|Gross Domestic Product (in million PPP int. $)|
|Total health expenditure (in million PPP int. $)|
|Gross domestic expenditures on R&D (GERD) * (in million PPP int. $)|
|World Bank Income Group|
|UN Region (Sub-Region)|
Note: Please see the User Guide for more information on the data sources that have provided this information and for explanation about the measures displayed here (e.g. purchasing power parity (PPP)). Most of the data in this section are derived from WHO's Global Health Expenditure Database.
* GERD relates to all areas of research and development, not only health. See below section Health R&D Expenditure, for the specific Health GERD Expenditure of .
|Life expectancy at birth|
|Total burden of disease in Disability-adjusted life years (DALYs)
(per 100,000 population)
|Age standardized mortality rate all causes (per 100,000 population)|
|Infant mortality rate
(probability of dying between birth and age 1 per 1000 live births)
|Under five mortality rate (per 1000 live births)|
|Maternal mortality ratio (per 10,000 live births)|
There are no Health R&D Expenditure data in the WHO Observatory on Health R&D for .
According to methods for developing estimates of countries’ health R&D expenditures as published by Røttingen et al (2013), the health R&D expenditures of were million PPP international dollars in .
|Total gross domestic expenditure on health related R&D (Health GERD) of|
|In million national currency|
|In million PPP international dollars|
|As % of gross domestic product (GDP)|
|As % of total health expenditure|
|As a % of gross domestic expenditures on R&D (GERD)|
|Per capita (in million PPP international dollars)|
|% performed by industry|
|% performed by non-market sectors|
Note: Expenditures in different countries cannot be easily compared to each other because different data sources are used for each country. More detail on the data sources for each country can be found here. Moreover, for some countries alternative estimates of health-related R&D are available, that have been compiled using different methods. For more information on this data source, its methods and on the measures displayed here (e.g. purchasing power parity (PPP)), please see the User Guide.
According to analyses by Policy Cures' G-FINDER survey, funders in spent on average thousand US Dollars per year on R&D for neglected areas from to , which constituted % of all funding for neglected areas over this period. The graph below shows the R&D funding provided by funders in in different years. Please note that the years reflected in the graph below are those for which funding data was reported.
Note: The data from Policy Cures' G-FINDER survey are limited to funding for product development and, for country specific information, the results display public and philanthropic funding only – i.e. private sector funding is excluded. Furthermore, the data are collected using specific definitions for diseases and limitations in terms of products to ensure that the data concern diseases that A) disproportionately affect people in developing countries, B) for which there is a need for new products, and C) for which there is market failure in developing these new products.
There are no registered clinical trials in in the ICTRP database
About the WHO ICTRP: the WHO ICTRP is the most inclusive global data source on clinical trials; it combines data from 16 clinical trial registries around the world.
Note: The graphs include both trials that are recruiting participants and trials that are not. More information on the search methodology and classifications used to develop these graphs can be found in the User Guide of the WHO Global Observatory on Health R&D. These data were last updated on 29 April 2016.
In there were publications on PubMed indexed as being about , constituting of all publications in 2014. The figure below displays how the number of publications about evolved over time.